Wide Range of Clinical Outcomes in Patients with Gliomatosis Cerebri Growth Pattern: A Clinical, Radiographic, and Histopathologic Study

K. Ina Ly, Derek H. Oakley, Alexander B. Pine, Matthew P. Frosch, Sy Han Chiou, Rebecca Betensky, Stuart R. Pomerantz, Fred H. Hochberg, Tracy T. Batchelor, Daniel P. Cahill, Jorg Dietrich

Research output: Contribution to journalArticle

Abstract

Background: The 2016 World Health Organization Classification of Central Nervous System Tumors categorizes gliomatosis cerebri growth pattern (GC) as a subgroup of diffuse infiltrating gliomas, defined by extent of brain involvement on magnetic resonance imaging (MRI). Clinical and radiographic features in GC patients are highly heterogeneous; however, prognosis has historically been considered poor. Subjects, Materials, and Methods: We performed a retrospective search for patients at our institution meeting radiographic criteria of primary, type I GC (defined as diffuse tumor infiltration without associated tumor mass and contrast enhancement on MRI) and analyzed their clinical, imaging, and histopathologic features. Results: A total of 34 patients met radiographic criteria of primary, type I GC, and 33 had a confirmed histologic diagnosis of an infiltrating glial neoplasm. Age >47 years at diagnosis was associated with worse overall survival (OS) compared with age ≤47 years (hazard ratio [HR] 1.04, 95% confidence interval [CI] 1.01–1.07, p =.003). Patients with grade 2 tumors demonstrated a trend for improved OS compared with those with grade 3 tumors (HR 2.65, 95% CI 0.99–7.08, p =.051). Except for brainstem involvement, extent or location of radiographic involvement did not detectably affect clinical outcome. IDH mutation status identified a subgroup of GC patients with particularly long survival up to 25 years and was associated with longer time to progression (HR 4.81, 95% CI 0.99–23.47, p =.052). Conclusion: Patients with primary, type I GC do not uniformly carry a poor prognosis, even in the presence of widespread radiographic involvement. Consistent with other reports, IDH mutation status may identify patients with improved clinical outcome. Molecular characterization, rather than MRI features, may be most valuable for prognostication and management of GC patients. Implications for Practice: Patients with gliomatosis cerebri growth pattern (GC) constitute a challenge to clinicians, given their wide range of clinical, histologic, and radiographic presentation, heterogeneous outcome patterns, and the lack of consensus on a standardized treatment approach. This study highlights that radiographic extent of disease—albeit category-defining—does not detectably influence survival and that IDH mutations may impact clinical outcome. Practicing oncologists should be aware that select GC patients may demonstrate exceptionally favorable survival times and prognosticate patients based on molecular markers, rather than imaging features alone.

Original languageEnglish (US)
JournalOncologist
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Neuroepithelial Neoplasms
Growth
Survival
Magnetic Resonance Imaging
Confidence Intervals
Neoplasms
Mutation
Central Nervous System Neoplasms
Glioma
Neuroglia
Brain Stem

Keywords

  • Diffuse infiltrating gliomas
  • Gliomatosis cerebri
  • Isocitrate dehydrogenase
  • Magnetic resonance imaging
  • Molecular markers

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Wide Range of Clinical Outcomes in Patients with Gliomatosis Cerebri Growth Pattern : A Clinical, Radiographic, and Histopathologic Study. / Ly, K. Ina; Oakley, Derek H.; Pine, Alexander B.; Frosch, Matthew P.; Chiou, Sy Han; Betensky, Rebecca; Pomerantz, Stuart R.; Hochberg, Fred H.; Batchelor, Tracy T.; Cahill, Daniel P.; Dietrich, Jorg.

In: Oncologist, 01.01.2018.

Research output: Contribution to journalArticle

Ly, K. Ina ; Oakley, Derek H. ; Pine, Alexander B. ; Frosch, Matthew P. ; Chiou, Sy Han ; Betensky, Rebecca ; Pomerantz, Stuart R. ; Hochberg, Fred H. ; Batchelor, Tracy T. ; Cahill, Daniel P. ; Dietrich, Jorg. / Wide Range of Clinical Outcomes in Patients with Gliomatosis Cerebri Growth Pattern : A Clinical, Radiographic, and Histopathologic Study. In: Oncologist. 2018.
@article{32b54469e9474be981ee8fbd68710cf8,
title = "Wide Range of Clinical Outcomes in Patients with Gliomatosis Cerebri Growth Pattern: A Clinical, Radiographic, and Histopathologic Study",
abstract = "Background: The 2016 World Health Organization Classification of Central Nervous System Tumors categorizes gliomatosis cerebri growth pattern (GC) as a subgroup of diffuse infiltrating gliomas, defined by extent of brain involvement on magnetic resonance imaging (MRI). Clinical and radiographic features in GC patients are highly heterogeneous; however, prognosis has historically been considered poor. Subjects, Materials, and Methods: We performed a retrospective search for patients at our institution meeting radiographic criteria of primary, type I GC (defined as diffuse tumor infiltration without associated tumor mass and contrast enhancement on MRI) and analyzed their clinical, imaging, and histopathologic features. Results: A total of 34 patients met radiographic criteria of primary, type I GC, and 33 had a confirmed histologic diagnosis of an infiltrating glial neoplasm. Age >47 years at diagnosis was associated with worse overall survival (OS) compared with age ≤47 years (hazard ratio [HR] 1.04, 95{\%} confidence interval [CI] 1.01–1.07, p =.003). Patients with grade 2 tumors demonstrated a trend for improved OS compared with those with grade 3 tumors (HR 2.65, 95{\%} CI 0.99–7.08, p =.051). Except for brainstem involvement, extent or location of radiographic involvement did not detectably affect clinical outcome. IDH mutation status identified a subgroup of GC patients with particularly long survival up to 25 years and was associated with longer time to progression (HR 4.81, 95{\%} CI 0.99–23.47, p =.052). Conclusion: Patients with primary, type I GC do not uniformly carry a poor prognosis, even in the presence of widespread radiographic involvement. Consistent with other reports, IDH mutation status may identify patients with improved clinical outcome. Molecular characterization, rather than MRI features, may be most valuable for prognostication and management of GC patients. Implications for Practice: Patients with gliomatosis cerebri growth pattern (GC) constitute a challenge to clinicians, given their wide range of clinical, histologic, and radiographic presentation, heterogeneous outcome patterns, and the lack of consensus on a standardized treatment approach. This study highlights that radiographic extent of disease—albeit category-defining—does not detectably influence survival and that IDH mutations may impact clinical outcome. Practicing oncologists should be aware that select GC patients may demonstrate exceptionally favorable survival times and prognosticate patients based on molecular markers, rather than imaging features alone.",
keywords = "Diffuse infiltrating gliomas, Gliomatosis cerebri, Isocitrate dehydrogenase, Magnetic resonance imaging, Molecular markers",
author = "Ly, {K. Ina} and Oakley, {Derek H.} and Pine, {Alexander B.} and Frosch, {Matthew P.} and Chiou, {Sy Han} and Rebecca Betensky and Pomerantz, {Stuart R.} and Hochberg, {Fred H.} and Batchelor, {Tracy T.} and Cahill, {Daniel P.} and Jorg Dietrich",
year = "2018",
month = "1",
day = "1",
doi = "10.1634/theoncologist.2018-0086",
language = "English (US)",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",

}

TY - JOUR

T1 - Wide Range of Clinical Outcomes in Patients with Gliomatosis Cerebri Growth Pattern

T2 - A Clinical, Radiographic, and Histopathologic Study

AU - Ly, K. Ina

AU - Oakley, Derek H.

AU - Pine, Alexander B.

AU - Frosch, Matthew P.

AU - Chiou, Sy Han

AU - Betensky, Rebecca

AU - Pomerantz, Stuart R.

AU - Hochberg, Fred H.

AU - Batchelor, Tracy T.

AU - Cahill, Daniel P.

AU - Dietrich, Jorg

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: The 2016 World Health Organization Classification of Central Nervous System Tumors categorizes gliomatosis cerebri growth pattern (GC) as a subgroup of diffuse infiltrating gliomas, defined by extent of brain involvement on magnetic resonance imaging (MRI). Clinical and radiographic features in GC patients are highly heterogeneous; however, prognosis has historically been considered poor. Subjects, Materials, and Methods: We performed a retrospective search for patients at our institution meeting radiographic criteria of primary, type I GC (defined as diffuse tumor infiltration without associated tumor mass and contrast enhancement on MRI) and analyzed their clinical, imaging, and histopathologic features. Results: A total of 34 patients met radiographic criteria of primary, type I GC, and 33 had a confirmed histologic diagnosis of an infiltrating glial neoplasm. Age >47 years at diagnosis was associated with worse overall survival (OS) compared with age ≤47 years (hazard ratio [HR] 1.04, 95% confidence interval [CI] 1.01–1.07, p =.003). Patients with grade 2 tumors demonstrated a trend for improved OS compared with those with grade 3 tumors (HR 2.65, 95% CI 0.99–7.08, p =.051). Except for brainstem involvement, extent or location of radiographic involvement did not detectably affect clinical outcome. IDH mutation status identified a subgroup of GC patients with particularly long survival up to 25 years and was associated with longer time to progression (HR 4.81, 95% CI 0.99–23.47, p =.052). Conclusion: Patients with primary, type I GC do not uniformly carry a poor prognosis, even in the presence of widespread radiographic involvement. Consistent with other reports, IDH mutation status may identify patients with improved clinical outcome. Molecular characterization, rather than MRI features, may be most valuable for prognostication and management of GC patients. Implications for Practice: Patients with gliomatosis cerebri growth pattern (GC) constitute a challenge to clinicians, given their wide range of clinical, histologic, and radiographic presentation, heterogeneous outcome patterns, and the lack of consensus on a standardized treatment approach. This study highlights that radiographic extent of disease—albeit category-defining—does not detectably influence survival and that IDH mutations may impact clinical outcome. Practicing oncologists should be aware that select GC patients may demonstrate exceptionally favorable survival times and prognosticate patients based on molecular markers, rather than imaging features alone.

AB - Background: The 2016 World Health Organization Classification of Central Nervous System Tumors categorizes gliomatosis cerebri growth pattern (GC) as a subgroup of diffuse infiltrating gliomas, defined by extent of brain involvement on magnetic resonance imaging (MRI). Clinical and radiographic features in GC patients are highly heterogeneous; however, prognosis has historically been considered poor. Subjects, Materials, and Methods: We performed a retrospective search for patients at our institution meeting radiographic criteria of primary, type I GC (defined as diffuse tumor infiltration without associated tumor mass and contrast enhancement on MRI) and analyzed their clinical, imaging, and histopathologic features. Results: A total of 34 patients met radiographic criteria of primary, type I GC, and 33 had a confirmed histologic diagnosis of an infiltrating glial neoplasm. Age >47 years at diagnosis was associated with worse overall survival (OS) compared with age ≤47 years (hazard ratio [HR] 1.04, 95% confidence interval [CI] 1.01–1.07, p =.003). Patients with grade 2 tumors demonstrated a trend for improved OS compared with those with grade 3 tumors (HR 2.65, 95% CI 0.99–7.08, p =.051). Except for brainstem involvement, extent or location of radiographic involvement did not detectably affect clinical outcome. IDH mutation status identified a subgroup of GC patients with particularly long survival up to 25 years and was associated with longer time to progression (HR 4.81, 95% CI 0.99–23.47, p =.052). Conclusion: Patients with primary, type I GC do not uniformly carry a poor prognosis, even in the presence of widespread radiographic involvement. Consistent with other reports, IDH mutation status may identify patients with improved clinical outcome. Molecular characterization, rather than MRI features, may be most valuable for prognostication and management of GC patients. Implications for Practice: Patients with gliomatosis cerebri growth pattern (GC) constitute a challenge to clinicians, given their wide range of clinical, histologic, and radiographic presentation, heterogeneous outcome patterns, and the lack of consensus on a standardized treatment approach. This study highlights that radiographic extent of disease—albeit category-defining—does not detectably influence survival and that IDH mutations may impact clinical outcome. Practicing oncologists should be aware that select GC patients may demonstrate exceptionally favorable survival times and prognosticate patients based on molecular markers, rather than imaging features alone.

KW - Diffuse infiltrating gliomas

KW - Gliomatosis cerebri

KW - Isocitrate dehydrogenase

KW - Magnetic resonance imaging

KW - Molecular markers

UR - http://www.scopus.com/inward/record.url?scp=85054809794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054809794&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2018-0086

DO - 10.1634/theoncologist.2018-0086

M3 - Article

C2 - 30097523

AN - SCOPUS:85054809794

JO - Oncologist

JF - Oncologist

SN - 1083-7159

ER -